Clinical Trial

Postpartum Low-Dose Aspirin and Preeclampsia

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 22, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this research study is to find out whether women with severe preeclampsia taking low-dose aspirin (LDA) for 3 weeks post-delivery will experience an improvement in endothelial function (measured as flow-mediated dilation - FMD) and severity of disease, as the effects of preeclampsia can persist postpartum. Women diagnosed with severe preeclampsia prior to delivery will be enrolled and randomized to receive either low-dose aspirin (81mg) or placebo to take daily for up to 3 weeks post-delivery. Exploratory objective includes healthy control postpartum patients without preeclampsia and not on LDA during pregnancy or postpartum in comparison with the primary study population affected by preeclampsia with severe features.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2018-09-10; most recent amendment 2026-01-21.
Status change: Not Yet Recruiting → Recruiting 2019-01-17
Trial Details
NCT Number NCT03667326
Lead Sponsor Columbia University
Conditions Preeclampsia Postpartum
Enrollment 100 participants
Start Date 2019-07-22
Primary Completion 2026-06 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-22